Cover Image
市場調查報告書

非酒精性脂肪性肝炎:全球臨床實驗趨勢

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016

出版商 GlobalData 商品編碼 240574
出版日期 內容資訊 英文 205 Pages
訂單完成後即時交付
價格
Back to Top
非酒精性脂肪性肝炎:全球臨床實驗趨勢 Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016
出版日期: 2016年02月17日 內容資訊: 英文 205 Pages
簡介

本報告提供非酒精性脂肪性肝炎相關臨床研究最新趨勢相關分析,提供您疾病·治療方法概要,及G7、E7各國的臨床實驗狀況,各地區、各階段的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 前五名國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:非酒精性脂肪性肝炎臨床實驗數量佔消化管疾病臨床實驗數量比率

各期臨床實驗數量: G7各國

G7各國的臨床實驗數量:各期

E7各國的臨床實驗數量:非酒精性脂肪性肝炎臨床實驗數量佔消化管疾病臨床實驗數量比率

各期臨床實驗數量: E7各國

E7各國的臨床實驗數量:各期

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

評估項目別臨床實驗數量

一定期間所採用的受驗人數

贊助商類別臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 非酒精性脂肪性肝炎 治療藥

有潛力的藥劑

  • 最新臨床實驗新聞:非酒精性脂肪性肝炎

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3230CTIDB

GlobalData's clinical trial report, "Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2016" provides an overview of Non-Alcoholic Steatohepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials
  • Prominent Drugs
    • Latest Clinical Trials News on Non-Alcoholic Steatohepatitis
      • Jan 26, 2016: Clinical Trial Results Show Synergy between NuSirt Technology and Metformin in Patients with Type 2 Diabetes
      • Jan 11, 2016: DURECT Announces Initiation of DUR-928 Dosing in Patients
      • Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis
      • Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928
      • Jan 05, 2016: Cempra Doses Initial Patient in Phase 2 Clinical Trial of Solithromycin in NASH
      • Dec 18, 2015: RG-125(AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 Being Developed for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development
      • Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
      • Dec 08, 2015: Tobira Therapeutics Announces Data Presentations Highlighting Cenicriviroc at HEP DART 2015
      • Dec 07, 2015: Intercept Pharmaceuticals Announces Initiation of Prospective Trial to Explore Effect of Combined OCA and Statin Therapy on Lipid Metabolism in NASH Patients
      • Nov 23, 2015: Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis
      • Nov 19, 2015: MediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia
      • Nov 18, 2015: NASH Clinical Trail Surpasses 25% Patient Recruitment Milestone
      • Nov 16, 2015: GENFIT Announces Pivotal Phase 3 Clinical Trial of Elafibranor in NASH Following Regulatory Input
      • Nov 14, 2015: Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015
      • Nov 12, 2015: Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting
      • Nov 11, 2015: DeuteRx Presents DRX-065 for the Treatment of NASH at the Annual Meeting of the American Association for the Study of Liver Diseases
      • Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*

List of Figures

  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Region (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, North America, Top Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*
  • Proportion of Non-Alcoholic Steatohepatitis to Gastrointestinal Clinical Trials, E7 Countries (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Phase (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics, Global, Clinical Trials by Trial Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, by End Point Status, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015
  • Non-Alcoholic Steatohepatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*
  • Non-Alcoholic Steatohepatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*
  • GlobalData Methodology
Back to Top